Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

20061,331 citationsJournal Articlebronze Open Access

Authors

Richard A. Rudick · Cleveland Clinic

William H. Stuart · Multiple Sclerosis Center of Atlanta

Peter A. Calabresi

Christian Confavreux · Institut NeuroMyoGène

Steven Galetta · University of Pennsylvania

Ernst-Wilhelm Radüe · University Hospital of Basel

Fred Lublin

Bianca Weinstock‐Guttman

Abstract

Natalizumab added to interferon beta-1a was significantly more effective than interferon beta-1a alone in patients with relapsing multiple sclerosis. Additional research is needed to elucidate the benefits and risks of this combination treatment. (ClinicalTrials.gov number, NCT00030966.).

Topics & Keywords

Multiple Sclerosis Research Studies Polyomavirus and related diseases Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 354, Issue 9, pp. 911-923

DOI: 10.1056/nejmoa044396

Field-Weighted Citation Impact: 55.47